


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the Application. Deletions are ~~strickethrough~~ and additions are underlined.

1 - 3. (Canceled)

4. (Currently amended) A pharmaceutical composition comprising; ~~use of~~ a compound to treat cancer disease represented by the following general formula (III), and the pharmaceutically acceptable salt or the isomer thereof ~~for the preparation of pharmaceutical composition to treat and prevent cancer diseases~~:



wherein

X is selected from the group consisting of a hydroxyl group, -NHOH, -NHOCH₂Ph,



and ;

R is selected from the group consisting of a lower alkyl, lower alkenyl, lower alkynyl, lower allyl group having C1 to C5 carbon atoms, a heterocyclic group ~~or~~ and aromatic aryl group;

n is an integer of 1 to 5; and

dotted line (≡) means single bond or double bond.

5. (Currently amended) The pharmaceutical composition use according to of claim 4, wherein said R is selected from the group consisting of ~~selected from~~ thiophenyl group, naphthyl group, pyrrolyl group, furyl group and biphenyl group.

6. (Currently amended) The pharmaceutical composition use according to of claim 5, wherein said compound is ~~one~~ selected from the group consisting of;

N-hydroxy-3-(1-naphthalene-2-ylmethyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-propionamide,

N-hydroxy-3-(1-methyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-propionamide,

3-(1-allyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-N-hydroxy-propionamide,

N-hydroxy-3-[1-(2-naphthalene-1-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,

N-hydroxy-3-[1-(2-naphthalene-2-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,

N-hydroxy-3-[2-oxo-1-(2-thiophen-2-yl-ethyl)-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,

3-[1-(3-biphenyl-4-yl-propyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-N-hydroxy-propionamide, and

N-hydroxy-3-[1-(3-naphthalene-2-yl-propyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide.

7 - 16. (Canceled)


17. (Currently amended) The ~~pharmaceutical composition use according to~~ pharmaceutical composition use according to claim 4, wherein said cancer disease ~~is selected from the group consisting of~~ comprises lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer or cancer of the anal region, stomach cancer, colon cancer, breast cancer, gynecologic tumors, Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphocytic ~~lymphomas~~ lymphomas, cancer of the bladder, cancer of the kidney or ureter, and neoplasms of the central nervous system.

18 - 20. (Canceled)

21. (New) The pharmaceutical composition of claim 6, wherein said compound is N-hydroxy-3-[1-(2-naphthalene-2-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide.

22. (New) The pharmaceutical composition claim 17 wherein said cancer disease is breast cancer.

23. (New - Withdrawn) A method to produce a beneficial effect comprising; administering a compound represented by the following general formula (III), and the pharmaceutically acceptable salt or the isomer thereof, to a Mammal in need of treatment of a cancer disease,



wherein

X is selected from the group consisting of a hydroxyl group, -NHOH, -NHOCH₂Ph,



R is selected from the group consisting of a lower alkyl, lower alkenyl, lower alkynyl, lower allyl group having C1 to C5 carbon atoms, a heterocyclic group and aromatic aryl group;

n is an integer of 1 to 5; and

dotted line (—) means single bond or double bond.

24. (New - Withdrawn) The method of Claim 23; wherein said R is selected from the group consisting of thiophenyl group, naphthyl group, pyrrolyl group, furyl group and biphenyl group.

25. (New - Withdrawn) The method of Claim 24; wherein said compound is selected from the group consisting of;

N-hydroxy-3-(1-naphthalene-2-ylmethyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-propionamide,

N-hydroxy-3-(1-methyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-propionamide,

3-(1-allyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-N-hydroxy-propionamide,

N-hydroxy-3-[1-(2-naphthalene-1-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,

N-hydroxy-3-[1-(2-naphthalene-2-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,

N-hydroxy-3-[2-oxo-1-(2-thiophen-2-yl-ethyl)-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,

3-[1-(3-biphenyl-4-yl-propyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-N-hydroxy-propionamide, and

N-hydroxy-3-[1-(3-naphthalene-2-yl-propyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide.

26. (New - Withdrawn) The method of Claim 25; wherein said compound is N-hydroxy-3-[1-(2-naphthalene-2-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide.

27. (New - Withdrawn) The method of Claim 23; wherein said cancer disease is selected from the group consisting of lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer or cancer of the anal region, stomach cancer, colon cancer, breast cancer, gynecologic tumors, Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, and neoplasms of the central nervous system.

28. (New - Withdrawn) The method of Claim 27; wherein said cancer disease is breast cancer.